SPINACI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.201
EU - Europa 2.695
AS - Asia 1.464
SA - Sud America 202
AF - Africa 76
Continente sconosciuto - Info sul continente non disponibili 5
Totale 7.643
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.111
PL - Polonia 938
IT - Italia 602
SG - Singapore 496
CN - Cina 458
RU - Federazione Russa 427
BR - Brasile 148
DE - Germania 145
GB - Regno Unito 144
VN - Vietnam 141
FR - Francia 123
HK - Hong Kong 117
FI - Finlandia 74
UA - Ucraina 67
KR - Corea 59
CA - Canada 58
ZA - Sudafrica 50
SE - Svezia 43
JP - Giappone 40
IN - India 34
TR - Turchia 34
IE - Irlanda 29
NL - Olanda 24
MX - Messico 20
AR - Argentina 17
EC - Ecuador 14
AT - Austria 13
BE - Belgio 12
BD - Bangladesh 11
ES - Italia 11
TW - Taiwan 11
PK - Pakistan 10
CO - Colombia 9
CZ - Repubblica Ceca 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 8
LT - Lituania 8
EG - Egitto 6
ID - Indonesia 6
IQ - Iraq 6
IR - Iran 6
EU - Europa 5
PE - Perù 5
LB - Libano 4
PH - Filippine 4
TN - Tunisia 4
UZ - Uzbekistan 4
HN - Honduras 3
JM - Giamaica 3
JO - Giordania 3
MA - Marocco 3
PY - Paraguay 3
AL - Albania 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CL - Cile 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
IL - Israele 2
MY - Malesia 2
NG - Nigeria 2
RS - Serbia 2
VE - Venezuela 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
KE - Kenya 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ME - Montenegro 1
MU - Mauritius 1
MW - Malawi 1
PA - Panama 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 7.643
Salva come PNG Salva come JPEG
Città #
Warsaw 842
Ashburn 287
Fairfield 287
Singapore 258
San Jose 181
Chandler 160
Council Bluffs 157
Woodbridge 156
Houston 139
Camerino 131
Jacksonville 129
Seattle 116
Hong Kong 100
Wilmington 99
Beijing 94
Cambridge 94
Kraków 93
Boardman 91
Ann Arbor 76
Dallas 71
Los Angeles 70
New York 62
Helsinki 53
Johannesburg 46
Ho Chi Minh City 44
Edinburgh 43
St Louis 40
Munich 38
Seoul 38
Rome 33
Tongling 33
Toronto 33
Frankfurt am Main 30
Santa Clara 30
Guangzhou 29
London 29
Dublin 28
Hanoi 28
Shanghai 28
Lawrence 27
Nanjing 27
Princeton 27
Istanbul 25
Tokyo 25
Lauterbourg 24
The Dalles 24
Trieste 24
Moscow 22
Ogden 22
Centro 21
Milan 20
San Mateo 20
São Paulo 20
Buffalo 18
Chicago 18
Ascoli Piceno 17
Orem 16
Columbus 15
Dong Ket 15
San Diego 14
San Francisco 14
Denver 13
Brussels 12
Chennai 12
Manchester 11
Nanchang 11
Phoenix 11
Turku 11
Atlanta 10
Kunming 10
Montreal 10
Pescara 10
Hillsboro 9
Mexico City 9
Tampa 9
Osimo 8
Poplar 8
Redondo Beach 8
Stockholm 8
Wuhan 8
Amsterdam 7
Brooklyn 7
Chongqing 7
Dearborn 7
Fabriano 7
Florence 7
Guayaquil 7
Hangzhou 7
Nuremberg 7
Rio de Janeiro 7
Tianjin 7
Biên Hòa 6
Boston 6
Bremen 6
Brno 6
Broomall 6
Lakeland 6
Mason City 6
Perugia 6
Salt Lake City 6
Totale 5.070
Salva come PNG Salva come JPEG
Nome #
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 454
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 407
Pharmacological characterization of the GPR17 receptor dual profile 396
GPR17 receptor modulators and their therapeutic implications: review of recent patents 390
The G Protein-Coupled Receptor GPR17: Overview and Update 372
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 366
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 357
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 334
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 268
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 264
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 256
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 247
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 239
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 236
New sensible method to quantize the intestinal absorption of receptor ligands 227
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 216
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 192
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 186
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 179
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 171
A2A Adenosine Receptor Antagonists and their Potential in Neurological Disorders 169
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 157
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 152
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 152
Casein kinase 1delta inhibitors as promising agents for neurodegenerative disorders 151
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 147
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 142
Combined therapy of A1AR agonists and A2AAR antagonists in neuroinflammation 134
A patent review of adenosine A2B receptor antagonists (2016-present) 131
Inhibition of Prostate Cancer Cell Growth Using Antagonists of the Adenosine A3 Receptors 121
New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity 109
Multipotent stromal cells from subcutaneous adipose tissue of normal weight and obese subjects: Modulation of their adipogenic differentiation by adenosine A1 receptor ligands 100
P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications 93
A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment 62
Radioligands Targeting the Purinergic P2X Receptors 51
A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Disease 48
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta 43
Beyond purinergic signaling: Dual ligand approaches to multitarget drug discovery 37
Adenine nucleotides as potent and selective GPR17 modulators 25
Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers 16
A Holistic Approach to Identifying a Positron Emission Tomography (PET) Tracer Candidate for In Vivo Imaging of Purinergic P2X7 Receptor in Neuroinflammation 11
Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents 10
Benzamide derivatives as allosteric ligands of the human and rat P2X7 receptor 6
Totale 7.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.582
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022417 31 100 13 8 9 12 35 32 41 41 50 45
2022/2023387 50 47 14 56 25 39 1 25 55 32 32 11
2023/2024398 21 23 27 23 18 27 21 43 55 20 24 96
2024/20251.458 72 25 93 68 71 73 201 321 143 87 119 185
2025/20262.454 126 134 196 345 274 162 349 229 189 190 168 92
2026/2027109 109 0 0 0 0 0 0 0 0 0 0 0
Totale 7.824